Observational study of wearable sensors (BioDigit MG) to track myasthenia gravis symptoms during treatment

You may qualify if

• Diagnosis of autoimmune MG with or without history of thymoma
• MGFA severity class IIa/b, IIIa/b or IVa/b at the screening visit
• Diagnosed gMG through one or more of the following:; Positive acetylcholine receptor antibody (AChR Ab) test, or; Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS), or; Documented positive response to standard MG therapies (e.g., AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors); Currently initiating treatment with VYVGART® or VYVGART Hytrulo®; Physically and cognitively able to provide informed consent and adhere to the study procedures, as determined by the investigator.; Ambulatory, defined as the ability to walk at least 10 meters independently, with or without the use of an assistive device.; Speaks and reads English fluently

You can't join if

• Inability to perform essential activities of daily living required for independent living, such as dressing, bathing, toileting, or eating without assistance.
• Presence of neurological or orthopedic conditions unrelated to MG that, in the investigator's judgment, significantly impair gait or daily functioning.
• Any clinically significant medical, laboratory, or psychiatric condition that, in the opinion of the investigator, could interfere with study participation or data integrity.
• Current residence in a long-term care or institutional facility (e.g., nursing home, skilled nursing facility), receipt of hospice care, or incarceration.
• MGFA severity classification of Class I or Class V (myasthenic crisis). Pregnant or breastfeeding women.
• Concurrent participation in another interventional clinical trial (participation in observational studies, biomarker studies, or registries is permitted).